Roche’s obesity drug boosts blood sugar control, drives 15.5 percent weight loss in mid-stage trial

GENEVA (Reuters): Swiss drugmaker Roche ‌said on Tuesday its experimental dual-acting obesity drug helped overweight or obese patients with type 2 diabetes lower blood sugar levels and lose an average 15. 5 percent of their body weight in a mid-stage trial. Roche is racing alongside large drugmakers, including AstraZeneca and Amgen, to break into the

Read full story on The Frontier Post